Agranulocytosis secondary to cancer chemotherapy

This code signifies a severe and potentially life-threatening reduction in granulocytes (a type of white blood cell) specifically caused by antineoplastic chemotherapy. This condition compromises the immune system, leaving the patient highly susceptible to infections. It is a direct adverse effect of cancer treatment.

Use this code when documentation explicitly states agranulocytosis as a direct consequence of chemotherapy administered for cancer. This typically occurs in patients undergoing treatment for various malignancies. Supporting documentation should include laboratory findings confirming low granulocyte counts and a clear link to chemotherapy.

• Always code the underlying malignancy first, followed by this code.
• Do not use this code for neutropenia of unspecified cause or neutropenia due to other medications.
• Ensure documentation specifies "agranulocytosis" or a severe reduction in granulocytes, not just general neutropenia, and clearly links it to chemotherapy.